首页> 美国卫生研究院文献>Journal of Clinical Oncology >A Phase 1 Trial and Pharmacokinetic Study of Cediranib an Orally Bioavailable Pan–Vascular Endothelial Growth Factor Receptor Inhibitor in Children and Adolescents With Refractory Solid Tumors

【2h】

A Phase 1 Trial and Pharmacokinetic Study of Cediranib an Orally Bioavailable Pan–Vascular Endothelial Growth Factor Receptor Inhibitor in Children and Adolescents With Refractory Solid Tumors

机译：Cediranib（一种口服生物利用性泛血管内皮生长因子受体抑制剂）在难治性实体瘤儿童和青少年中的1期试验和药代动力学研究。

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposeTo determine the toxicity profile, dose-limiting toxicities (DLTs), maximum-tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of cediranib administered orally, once daily, continuously in children and adolescents with solid tumors.

机译：目的确定每天一次口服西地拉尼对患有实体瘤的儿童和青少年的毒性特征，剂量限制毒性（DLT），最大耐受剂量（MTD），药代动力学和药效学。

著录项

期刊名称 Journal of Clinical Oncology
作者
Elizabeth Fox; Richard Aplenc; Rochelle Bagatell; Meredith K. Chuk; Eva Dombi; Wendy Goodspeed; Anne Goodwin; Marie Kromplewski; Nalini Jayaprakash; Marcelo Marotti; Kathryn H. Brown; Barbara Wenrich; Peter C. Adamson; Brigitte C. Widemann; Frank M. Balis;
展开▼
作者单位

展开▼
年(卷),期 -1(28),35
年度 -1
页码 5174–5181
总页数 8
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors. [J] . Fox E, Aplenc R, Bagatell R, Journal of Clinical Oncology . 2010,第35期

机译：西地那尼（一种口服生物可利用的泛血管内皮生长因子受体抑制剂）在患有顽固性实体瘤的儿童和青少年中的一项1期试验和药代动力学研究。
2. A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors [J] . Kieran Mark W., Chi Susan, Goldman Stewart, Child's nervous system: ChNS : official journal of the International Society for Pediatric Neurosurgery . 2015,第9期

机译：复发性或难治性原发性中枢神经系统肿瘤患儿西地尼布（AZD2171）（口服生物可用的pan-VEGFR抑制剂）的I期试验和PK研究
3. Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors [J] . Su Jin Lee, Seon Young Lee, Weon Sup Lee, Investigational new drugs. . 2017,第6期

机译：Tanibirumab的I阶段试验和药代动力学研究，难治性固体肿瘤患者血管内皮生长因子受体2的全人单克隆抗体
4. Vascular endothelial growth factor receptor 2 binding peptide:Targeting vascular endothelial cells [C] . Laimute Taraseviciene-stewart, John M.Stewart, Lajos Gera, European Peptide Symposium . 2002

机译：血管内皮生长因子受体2结合肽：靶向血管内皮细胞
5. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
6. A Phase I trial and PK Study of Cediranib (AZD2171) an Orally Bioavailable Pan-VEGFR Inhibitor in Children with Recurrent or Refractory Primary CNS Tumors [O] . Mark W. Kieran, Susan Chi, Stewart Goldman, -1

机译：复发或难治性原发性中枢神经系统肿瘤儿童口服生物可利用的泛-VEGFR抑制剂塞地尼布（AZD2171）的I期试验和PK研究
7. A Phase 1 Trial and Pharmacokinetic Study of Cediranib, an Orally Bioavailable Pan–Vascular Endothelial Growth Factor Receptor Inhibitor, in Children and Adolescents With Refractory Solid Tumors [O] . Fox, Elizabeth, Aplenc, Richard, Bagatell, Rochelle, 2010

机译：Cediranib（一种口服生物利用性泛血管内皮生长因子受体抑制剂）在难治性实体瘤儿童和青少年中的1期试验和药代动力学研究。

A Phase 1 Trial and Pharmacokinetic Study of Cediranib an Orally Bioavailable Pan–Vascular Endothelial Growth Factor Receptor Inhibitor in Children and Adolescents With Refractory Solid Tumors

摘要

著录项

相似文献

相关主题

期刊订阅